Sara Lonardi

Research interests

Publications

• Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer

  New England Journal of Medicine · 2025 · https://doi.org/10.1056/nejmoa2503119

• Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer

  New England Journal of Medicine · 2024 · https://doi.org/10.1056/nejmoa2402141

• Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study

  The Lancet · 2023 · https://doi.org/10.1016/s0140-6736(23)00772-9

• Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study

  The Lancet Oncology · 2023 · https://doi.org/10.1016/s1470-2045(23)00242-5

• Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial

  The Lancet · 2023 · https://doi.org/10.1016/s0140-6736(23)02033-0

• Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study

  The Lancet Oncology · 2023 · https://doi.org/10.1016/s1470-2045(23)00541-7

• Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population

  European Journal of Cancer · 2022 · https://doi.org/10.1016/j.ejca.2022.11.017

• Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial

  The Lancet Oncology · 2022 · https://doi.org/10.1016/s1470-2045(22)00274-1

• Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142

  Annals of Oncology · 2022 · https://doi.org/10.1016/j.annonc.2022.06.008

• Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis

  ESMO Open · 2022 · https://doi.org/10.1016/j.esmoop.2022.100591

• The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer

  Nature · 2021 · https://doi.org/10.1038/s41586-021-04161-3

• The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials

  British Journal of Cancer · 2020 · https://doi.org/10.1038/s41416-020-0894-7

• Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

  The Lancet Oncology · 2020 · https://doi.org/10.1016/s1470-2045(19)30862-9

• Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

  The Lancet Oncology · 2020 · https://doi.org/10.1016/s1470-2045(19)30862-9

• Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100

  Journal of Clinical Oncology · 2020 · https://doi.org/10.1200/jco.20.00892

• Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

  The Lancet Oncology · 2019 · https://doi.org/10.1016/s1470-2045(18)30791-5

• Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1908075

• Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan

  JAMA Oncology · 2018 · https://doi.org/10.1001/jamaoncol.2018.5080

• Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer

  Journal of Clinical Oncology · 2018 · https://doi.org/10.1200/jco.2017.76.9901

• Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

  The Lancet Oncology · 2017 · https://doi.org/10.1016/s1470-2045(17)30422-9

• Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(16)00150-9

• FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study

  The Lancet Oncology · 2015 · https://doi.org/10.1016/s1470-2045(15)00122-9

• Assessment of a HER2 scoring system for colorectal cancer: results from a validation study

  Modern Pathology · 2015 · https://doi.org/10.1038/modpathol.2015.98

• Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

  The Lancet Oncology · 2015 · 10.1016/s1470-2045(15)70127-0

• Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer

  New England Journal of Medicine · 2014 · https://doi.org/10.1056/nejmoa1403108

• Primary Tumor Response to Preoperative Chemoradiation With or Without Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Results of the STAR-01 Randomized Phase III Trial

  Journal of Clinical Oncology · 2011 · https://doi.org/10.1200/jco.2010.34.4911

Current projects

No projects listed.